Jhe United States International Trade Commission has agreed to investigate whether two companies misappropriated trade secrets as part of plans to eventually market a biosimilar version of Humira, a top-selling biologic drug sold by AbbVie ( ABBV) for the treatment of rheumatoid arthritis and other conditions.
The decision follows a complaint filed last month by AbbVie, which is bracing for a handful of biosimilar competitors next year and hopes to prevent Alvotech and its partner, Teva Pharmaceuticals (TEVA), from selling a version of Humira again. earlier. Alvotech is awaiting regulatory approval for its drug after pandemic travel restrictions delayed factory inspections by the Food and Drug Administration.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
TO START
What is that?
STAT+ is STAT’s premium subscription service for in-depth coverage and analysis of biotechnology, pharmaceuticals, policy and life sciences. Our award-winning team covers news from Wall Street, political developments in Washington, early scientific breakthroughs and clinical trial results, and healthcare disruptions in Silicon Valley and beyond.
What’s included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerful team of journalists
- Newsletters reserved for subscribers
- Daily newsletters to inform you about the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our journalists and leading industry experts in live video chats
- Exclusive industry events
- Premium access to subscriber-only networking events nationwide
- The best journalists in the industry
- The most trusted, best-connected newsroom in healthcare
- And much more
- Exclusive interviews with industry leaders, profiles and premium tools, like our CRISPR Trackr.
